From the smallest biotech to the biggest pharmaceutical stock, The Motley Fool's Market Checkup covers the health-care sector's biggest headlines, hottest market movers, and Obamacare's ongoing rollout.
In this segment from Thursday's episode, health-care analyst David Williamson takes a look at the third-quarter earnings report from Vivus (NASDAQ:VVUS). Shares fell more than 12% on the news that the company's revenue from its drug Qsymia was nowhere near what investors were hoping for. While the company showed 35% quarter-to-quarter growth, this, too, fell drastically short of the exponential growth investors were hoping for from a pharmaceutical company with a potentially blockbuster new drug rollout. David looks closely into Vivus' prospects, and lists a few other headwinds investors should be aware of.
Follow David on Twitter: @MotleyDavid.